The wide use of chemotherapeutic drugs that are substrates of ABCB1 including paclitaxel and doxorubicin could lead to the activation/overexpression of ABCB1, at the same time, the overexpression of ABCB1 confers resistance to these drugs in cancer cells and cancer patients (Genovese et al., 2017). This evidence concerns the gene ABCB1 and cancer.